RNS Number : 6528G

GlaxoSmithKline PLC

26 November 2020

Issued: 26 November 2020, London UK - LSE Announcement

Publication of Supplementary Prospectus

The following base prospectus dated 26 November 2020 has been approved by the UK Listing Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. GBP20,000,000,000 Euro Medium Term Note Programme

Copies of the supplementary prospectus have been submitted to the UK Listing Authority's National Storage Mechanism submission portal via the Electronic Submission System. The base prospectus will shortly be available for inspection at and can be downloaded from:


For further information, please contact:

GlaxoSmithKline plc

980 Great West Road




United Kingdom


 UK Media enquiries:          David Mawdsley     (020) 8047 5564 
   Simon Steel                                    (020) 8047 3763 
 European Analyst/Investor 
  enquiries:                  James Dodwell      (020) 8047 2406 
   Danielle Smith                                 (020) 8047 0932 


Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above

 GlaxoSmithKline plc 
  Registered in England & Wales: 
  No. 3888792 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 26, 2020 07:35 ET (12:35 GMT)

Glaxosmithkline (LSE:GSK)
過去 株価チャート
から 12 2020 まで 1 2021 Glaxosmithklineのチャートをもっと見るにはこちらをクリック
Glaxosmithkline (LSE:GSK)
過去 株価チャート
から 1 2020 まで 1 2021 Glaxosmithklineのチャートをもっと見るにはこちらをクリック